OncoMatch/Clinical Trials/NCT05544240
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Is NCT05544240 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SV-101 for metastatic cancer.
Treatment: SV-101 — SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/L; Lymphocyte count ≥ 1.0 x 10^9/L; Platelet count ≥ 100 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; Bone marrow function without transfusion 30 days before first dosing
Kidney function
Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 or creatinine clearance calculated by Cockcroft-Gault equation ≥30 mL/
Liver function
Alanine aminotransferase ≤ 3x ULN; Aspartate aminotransferase ≤ 3x ULN; Total bilirubin ≤ ULN or ≤ 1.5x ULN with direct bilirubin ≤ ULN in subjects with documented Gilbert's Syndrome; Patients with liver metastases ≤5x ULN
Cardiac function
Has undergone a cardiac work-up and received cardiac clearance two months before first treatment
Adequate bone marrow, renal, and hepatic function, defined as follows: ... Has undergone a cardiac work-up and received cardiac clearance two months before first treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify